Mark P Fereshteh
Overview
Explore the profile of Mark P Fereshteh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nair S, Kumar S, Paidi V, Sistla R, Kantheti D, Polimera S, et al.
ACS Med Chem Lett
. 2020 Jul;
11(7):1402-1409.
PMID: 32676146
IRAK4 is an attractive therapeutic target for the treatment of inflammatory conditions. Structure guided optimization of a nicotinamide series of inhibitors has been expanded to explore the IRAK4 front pocket....
2.
Velaparthi U, Padmakar Darne C, Warrier J, Liu P, Rahaman H, Augustine-Rauch K, et al.
ACS Med Chem Lett
. 2020 Feb;
11(2):172-178.
PMID: 32071685
Novel imidazole-based TGFβR1 inhibitors were identified and optimized for potency, selectivity, and pharmacokinetic and physicochemical characteristics. Herein, we report the discovery, optimization, and evaluation of a potent, selective, and orally...
3.
Zhang Y, Zhao Y, Tebben A, Sheriff S, Ruzanov M, Fereshteh M, et al.
ACS Med Chem Lett
. 2018 Nov;
9(11):1117-1122.
PMID: 30429955
The multifunctional cytokine TGFβ plays a central role in regulating antitumor immunity. It has been postulated that inhibition of TGFβ signaling in concert with checkpoint blockade will provide improved and...
4.
Fan Y, Naglich J, Koenitzer J, Ribeiro H, Lippy J, Blum J, et al.
SLAS Discov
. 2018 Jun;
23(7):742-750.
PMID: 29873570
Enhancing antitumor activities of the human immune system is a clinically proven approach with the advent of monoclonal antibodies recognizing programmed cell death protein-1 (PD1) receptors on immune cell surfaces....
5.
Villaume M, Sella E, Saul G, Borzilleri R, Fargnoli J, Johnston K, et al.
ACS Cent Sci
. 2016 May;
2(1):27-31.
PMID: 27163023
The fungal-derived Taiwanese natural product antroquinonol A has attracted both academic and commercial interest due to its reported exciting biological properties. This reduced quinone is currently in phase II trials...
6.
Fereshteh M, Li X, Li S, Fan Y, Zhang R, Farr G, et al.
J Biomol Screen
. 2016 May;
21(8):866-74.
PMID: 27142718
Oral agents targeting Janus-associated kinases (JAKs) are promising new agents in clinical development. To better understand the relationship between JAK inhibition and biological outcome, compounds targeting JAKs were evaluated in...
7.
Kotula J, Sun J, Li M, Pratico E, Fereshteh M, Ahrens D, et al.
PLoS One
. 2014 Apr;
9(4):e93441.
PMID: 24736311
Unlabelled: β-arrestins, ubiquitous cellular scaffolding proteins that act as signaling mediators of numerous critical cellular pathways, are attractive therapeutic targets because they promote tumorigenesis in several tumor models. However, targeting...
8.
Oh A, Lahusen J, Chien C, Fereshteh M, Zhang X, Dakshanamurthy S, et al.
Mol Cell Biol
. 2008 Sep;
28(21):6580-93.
PMID: 18765637
Overexpression and activation of the steroid receptor coactivator amplified in breast cancer 1 (AIB1)/steroid receptor coactivator-3 (SRC-3) have been shown to have a critical role in oncogenesis and are required...
9.
Fereshteh M, Tilli M, Kim S, Xu J, OMalley B, Wellstein A, et al.
Cancer Res
. 2008 May;
68(10):3697-706.
PMID: 18483252
Overexpression of the oncogene amplified in breast cancer 1 (AIB1)/steroid receptor coactivator-3 (SRC-3) induces mammary tumorigenesis in mice. In breast cancer, high levels of AIB1/SRC-3 and the growth factor receptor...